OBSIDIAN THERAPEUTICS, INC. (OBX) Current Ratio
- Current ratio · latest quarter: Value 2.30×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 2.30× | Current assets / current liabilities. $46.36M ÷ $20.20M ≈ 2.30× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 46.36M USD | Assets, Current |
| Current obligations | 20.20M USD | Liabilities, Current |
| Cash and equivalents | 17.98M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 16.46M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 365.00K USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $46.36M | $20.20M | $17.98M | $16.46M | (m) | (m) | $365.00K | (m) | 2.30× |
| 2025-12-31 | $81.52M | $15.36M | $40.41M | $40.08M | (m) | (m) | $12.00K | (m) | 5.31× |
| 2024-12-31 | $172.85M | $16.09M | $49.76M | $118.51M | (m) | (m) | $1.82M | (m) | 10.75× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |